Literature DB >> 29692236

Interstage Outcomes in Infants With Single Ventricle Heart Disease Comparing Home Monitoring Technology to Three-Ring Binder Documentation: A Randomized Crossover Study.

Michael Bingler1, Lori A Erickson2, Kimberly J Reid2, Brian Lee2, James O'Brien2, Johnathan Apperson2, Kathy Goggin2, Girish Shirali2.   

Abstract

BACKGROUND: Interstage outcomes for infants with single ventricle remain suboptimal. We have previously described a tablet PC-based platform Cardiac High Acuity Monitoring Program (CHAMP) for remote monitoring which provides immediate access to data, videos, and instant alerts to our single ventricle care team.
METHODS: This study compares traditional three-ring binder monitoring (Binder) to CHAMP using a randomized crossover design to evaluate mortality, resource utilization, and caregiver experience. At discharge, all single ventricle infants were monitored using Binder and randomized to receive CHAMP at either one or two months postdischarge. One month after randomization, caregivers could choose either Binder or CHAMP for the remainder of the interstage period. Caregivers experience was recorded using surveys.
RESULTS: Enrollment included 31 single ventricle infants from May 2014 to June 2015. There was no interstage mortality over 4,911 total interstage days (median: 144/patient). Of 73 readmissions, 45 were unplanned. Of the initial 23 unplanned readmissions, 13 were found to have been based on data obtained exclusively through CHAMP (as instant alerts or based on data review) rather than caregiver concerns. Due to concerns regarding patient safety, additional enrollment was stopped. The CHAMP use was associated with significantly fewer unplanned intensive care unit days/100 interstage days, shorter delays in care, lower resource utilization at readmissions, and lower incidence of interstage growth failure and was preferred by a majority of caregivers.
CONCLUSIONS: These findings suggest that CHAMP may offer benefits over Binder (improved interstage outcomes, delays in care, and caregiver experience). These findings should be tested across multiple centers in larger populations.

Entities:  

Keywords:  home monitoring; interstage; resource utilization; single ventricle

Mesh:

Year:  2018        PMID: 29692236     DOI: 10.1177/2150135118762401

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  5 in total

1.  Invasive Cardiac Procedures in Interstage Single Ventricle Patients in Emergent Hospitalizations.

Authors:  Brena S Haughey; Shelby C White; Garrett S Pacheco; Kenneth A Fox; Michael D Seckeler
Journal:  Pediatr Cardiol       Date:  2019-11-08       Impact factor: 1.655

2.  Does remote patient monitoring reduce acute care use? A systematic review.

Authors:  Monica L Taylor; Emma E Thomas; Centaine L Snoswell; Anthony C Smith; Liam J Caffery
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

3.  Initial Experience with Telemedicine for Interstage Monitoring in Infants with Palliated Congenital Heart Disease.

Authors:  Alyson Stagg; Therese M Giglia; Monique M Gardner; Bonnie F Offit; Kate M Fuller; Shobha S Natarajan; David A Hehir; Anita L Szwast; Jonathan J Rome; Chitra Ravishankar; Benjamin L Laskin; Tamar J Preminger
Journal:  Pediatr Cardiol       Date:  2022-09-01       Impact factor: 1.838

Review 4.  Telehealth for Pediatric Cardiology Practitioners in the Time of COVID-19.

Authors:  Devyani Chowdhury; Kyle D Hope; Lindsay C Arthur; Sharon M Weinberger; Christina Ronai; Jonathan N Johnson; Christopher S Snyder
Journal:  Pediatr Cardiol       Date:  2020-07-12       Impact factor: 1.655

5.  Interstage Home Monitoring for Infants With Single Ventricle Heart Disease: Education and Management: A Scientific Statement From the American Heart Association.

Authors:  Nancy A Rudd; Nancy S Ghanayem; Garick D Hill; Linda M Lambert; Kathleen A Mussatto; Jo Ann Nieves; Sarah Robinson; Girish Shirali; Michelle M Steltzer; Karen Uzark; Nancy A Pike
Journal:  J Am Heart Assoc       Date:  2020-08-11       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.